Regencell Bioscience (RGC) has had the highest return since January 1, 2025 by a US stock with a market cap of $2,004+, returning 9,638%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 9,638.02% |
QMMM Holdings Limited Ordinary Shares (QMMM) | 9,155.81% |
Diginex Limited Ordinary Shares (DGNX) | 1,777.93% |
Abivax SA American Depositary Shares (ABVX) | 1,432.18% |
Zepp Health (ZEPP) | 984.62% |
DeFi Development (DFDV) | 962.57% |
Oncology Institute (TOI) | 903.27% |
Newegg Commerce (NEGG) | 852% |
Abits (ABTS) | 827.9% |
FiEE (FIEE) | 771.56% |
Cidara Therapeutics (CDTX) | 715.12% |
Palvella Therapeutics (PVLA) | 691.65% |
Relmada Therapeutics (RLMD) | 682.58% |
Celcuity LLC (CELC) | 656.43% |
Lizhi (SOGP) | 601.47% |
TMC the metals (TMC) | 577.19% |
Nanobiotix (NBTX) | 576.21% |
Anbio Biotechnology Class A Ordinary Shares (NNNN) | 556.27% |
Avino Silver & Gold Mines (ASM) | 514.29% |
GRAIL, LLC (GRAL) | 467.85% |
Sandisk (SNDK) | 454.42% |
ThredUp (TDUP) | 451.39% |
Inhibrx Biosciences (INBX) | 441.87% |
AXT (AXTI) | 417.12% |
Global Interactive Technologies (GITS) | 410.37% |
